Spero Therapeutics (NASDAQ:SPRO) Shares Cross Below Two Hundred Day Moving Average of $1.52

Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.52 and traded as low as $1.33. Spero Therapeutics shares last traded at $1.34, with a volume of 54,156 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a research note on Thursday, April 4th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Spero Therapeutics in a research note on Thursday, May 16th.

Spero Therapeutics Stock Down 3.0 %

The firm has a market capitalization of $70.19 million, a PE ratio of 3.02 and a beta of 0.64. The business’s fifty day moving average price is $1.46 and its 200 day moving average price is $1.52.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.17). Spero Therapeutics had a return on equity of 35.42% and a net margin of 21.09%. The company had revenue of $9.27 million for the quarter, compared to analysts’ expectations of $16.80 million. As a group, sell-side analysts forecast that Spero Therapeutics, Inc. will post -1.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SPRO. Virtu Financial LLC purchased a new position in shares of Spero Therapeutics in the 1st quarter worth about $31,000. Murchinson Ltd. grew its stake in Spero Therapeutics by 1.3% during the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after purchasing an additional 11,210 shares in the last quarter. Acadian Asset Management LLC increased its holdings in Spero Therapeutics by 121.8% during the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after purchasing an additional 418,742 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Spero Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock valued at $2,844,000 after purchasing an additional 9,675 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Spero Therapeutics during the 4th quarter valued at approximately $1,570,000. Institutional investors and hedge funds own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.